Go Pro
→ Trump Takes Emergency Action - Plus Elon Musk's New Venture (From Altimetry) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
$106.02
-0.8%		$92.63
$18.08
▼
$114.55
$5.80B1.2980,812 shs841,888 shs
Erasca, Inc. stock logo
ERAS
Erasca
$17.84
-1.7%		$16.18
$1.33
▼
$24.28
$5.55B0.666.42 million shs2.75 million shs
Grifols, S.A. stock logo
GRFS
Grifols
$7.86
-0.1%		$7.51
$6.96
▼
$10.88
$5.35B0.66685,776 shs373,259 shs
Xencor, Inc. stock logo
XNCR
Xencor
$19.40
-4.0%		$14.86
$6.92
▼
$21.76
$1.44B0.86843,358 shs714,400 shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
0.00%+2.94%+13.33%+22.31%+419.28%
Erasca, Inc. stock logo
ERAS
Erasca
0.00%-5.02%-1.73%+80.96%+1,205.76%
Grifols, S.A. stock logo
GRFS
Grifols
0.00%+3.83%+9.92%-4.37%-26.99%
Xencor, Inc. stock logo
XNCR
Xencor
0.00%+3.96%+34.73%+59.26%+153.26%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
$106.02
-0.8%		$92.63
$18.08
▼
$114.55
$5.80B1.2980,812 shs841,888 shs
Erasca, Inc. stock logo
ERAS
Erasca
$17.84
-1.7%		$16.18
$1.33
▼
$24.28
$5.55B0.666.42 million shs2.75 million shs
Grifols, S.A. stock logo
GRFS
Grifols
$7.86
-0.1%		$7.51
$6.96
▼
$10.88
$5.35B0.66685,776 shs373,259 shs
Xencor, Inc. stock logo
XNCR
Xencor
$19.40
-4.0%		$14.86
$6.92
▼
$21.76
$1.44B0.86843,358 shs714,400 shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
0.00%+2.94%+13.33%+22.31%+419.28%
Erasca, Inc. stock logo
ERAS
Erasca
0.00%-5.02%-1.73%+80.96%+1,205.76%
Grifols, S.A. stock logo
GRFS
Grifols
0.00%+3.83%+9.92%-4.37%-26.99%
Xencor, Inc. stock logo
XNCR
Xencor
0.00%+3.96%+34.73%+59.26%+153.26%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
2.93
Moderate Buy$117.8211.13% Upside
Erasca, Inc. stock logo
ERAS
Erasca
2.64
Moderate Buy$21.6421.28% Upside
Grifols, S.A. stock logo
GRFS
Grifols
1.75
Reduce$10.0027.23% Upside
Xencor, Inc. stock logo
XNCR
Xencor
2.50
Moderate Buy$24.2525.00% Upside

Current Analyst Ratings Breakdown

Latest XNCR, DNTH, ERAS, and GRFS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/31/2026
Grifols, S.A. stock logo
GRFS
Grifols
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D+) ➝ Sell (D)
7/30/2026
Xencor, Inc. stock logo
XNCR
Xencor
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$26.00
7/20/2026
Erasca, Inc. stock logo
ERAS
Erasca
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetEqual Weight$12.00 ➝ $21.00
7/17/2026
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
7/14/2026
Erasca, Inc. stock logo
ERAS
Erasca
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
7/14/2026
Erasca, Inc. stock logo
ERAS
Erasca
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$24.00
7/14/2026
Erasca, Inc. stock logo
ERAS
Erasca
HSBC Holdings plc logo
HSBC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$20.00
7/14/2026
Erasca, Inc. stock logo
ERAS
Erasca
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
7/14/2026
Erasca, Inc. stock logo
ERAS
Erasca
Bank of America Corporation logo
Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$16.00 ➝ $18.00
7/7/2026
Grifols, S.A. stock logo
GRFS
Grifols
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong Sell ➝ Hold
7/7/2026
Xencor, Inc. stock logo
XNCR
Xencor
Truist Financial Corporation logo
Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$29.00 ➝ $27.00
(Data available from 8/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
$1.34M4,338.09N/AN/A$11.41 per share9.29
Erasca, Inc. stock logo
ERAS
Erasca
N/AN/AN/AN/A$1.05 per shareN/A
Grifols, S.A. stock logo
GRFS
Grifols
$8.51B0.63$1.41 per share5.56$12.64 per share0.62
Xencor, Inc. stock logo
XNCR
Xencor
$97.36M14.77N/AN/A$8.90 per share2.18
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
-$162.34M-$4.13N/AN/AN/A-12,998.50%-27.30%-25.91%8/6/2026 (Estimated)
Erasca, Inc. stock logo
ERAS
Erasca
-$124.55M-$0.93N/AN/AN/AN/A-35.31%-29.49%8/11/2026 (Estimated)
Grifols, S.A. stock logo
GRFS
Grifols
$454.82M$0.1941.376.000.295.54%6.21%2.39%N/A
Xencor, Inc. stock logo
XNCR
Xencor
-$91.92M-$2.29N/AN/AN/A-177.10%-28.77%-20.52%8/5/2026 (Estimated)

Latest XNCR, DNTH, ERAS, and GRFS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/11/2026Q2 2026
Erasca, Inc. stock logo
ERAS
Erasca
-$0.1114N/AN/AN/AN/AN/A
8/6/2026Q2 2026
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
-$0.8463N/AN/AN/A$0.30 millionN/A
8/5/2026Q2 2026
Xencor, Inc. stock logo
XNCR
Xencor
-$0.8018N/AN/AN/A$18.89 millionN/A
5/11/2026Q1 2026
Erasca, Inc. stock logo
ERAS
Erasca
-$0.1150-$0.60-$0.4850-$0.60N/AN/A
5/6/2026Q1 2026
Xencor, Inc. stock logo
XNCR
Xencor
-$0.7468-$1.71-$0.9632-$1.71$27.86 million$4.52 million
5/5/2026Q1 2026
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
-$1.0719-$0.85+$0.2219-$0.85$0.40 million$0.46 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
N/AN/AN/AN/AN/A
Erasca, Inc. stock logo
ERAS
Erasca
N/AN/AN/AN/AN/A
Grifols, S.A. stock logo
GRFS
Grifols
$0.232.93%N/A121.05%N/A
Xencor, Inc. stock logo
XNCR
Xencor
N/AN/AN/AN/AN/A

Latest XNCR, DNTH, ERAS, and GRFS Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
6/19/2026
Grifols, S.A. stock logo
GRFS
Grifols
special$0.09457/2/20267/2/20267/9/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
N/A
29.25
29.25
Erasca, Inc. stock logo
ERAS
Erasca
N/A
9.52
9.52
Grifols, S.A. stock logo
GRFS
Grifols
1.10
2.37
0.81
Xencor, Inc. stock logo
XNCR
Xencor
N/A
6.57
6.57

Institutional Ownership

CompanyInstitutional Ownership
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
47.53%
Erasca, Inc. stock logo
ERAS
Erasca
67.78%
Grifols, S.A. stock logo
GRFS
Grifols
N/A
Xencor, Inc. stock logo
XNCR
Xencor
N/A

Insider Ownership

CompanyInsider Ownership
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
3.02%
Erasca, Inc. stock logo
ERAS
Erasca
14.20%
Grifols, S.A. stock logo
GRFS
Grifols
0.19%
Xencor, Inc. stock logo
XNCR
Xencor
5.08%
CompanyEmployeesShares OutstandingFree FloatOptionable
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
8054.67 million53.02 millionOptionable
Erasca, Inc. stock logo
ERAS
Erasca
120310.98 million266.83 millionOptionable
Grifols, S.A. stock logo
GRFS
Grifols
25,247680.58 million679.28 millionOptionable
Xencor, Inc. stock logo
XNCR
Xencor
28074.14 million70.38 millionOptionable

Recent News About These Companies

Xencor (NASDAQ:XNCR) Trading Down 3.9% - Here's Why
 |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/xencor-nasdaqxncr-trading-down-39-heres-why-2026-08-03/
Xencor’s XmAb412 Enters First-in-Human Testing: What Early-Stage Investors Should Watch
 |  tipranks.comhttps://www.tipranks.com/news/company-announcements/xencors-xmab412-enters-first-in-human-testing-what-early-stage-investors-should-watch?utm_source=marketbeat.com&utm_medium=referral
Xencor (NASDAQ:XNCR) Earns Outperform Rating from Wedbush
August 1 at 3:25 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30934541
Xencor (NASDAQ:XNCR) Reaches New 1-Year High - Should You Buy?
July 30, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/xencor-nasdaqxncr-reaches-new-1-year-high-should-you-buy-2026-07-30/
Wedbush Reiterates Outperform Rating for Xencor (NASDAQ:XNCR)
July 30, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/wedbush-reiterates-outperform-rating-for-xencor-nasdaqxncr-2026-07-30/
Xencor to Receive $105 Million From Alexion to Resolve Ultomiris® U.S. Royalty Matter
July 29, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/xencor-receive-105-million-alexion-200100195.html
Xencor (XNCR) Expected to Post Earnings on Wednesday
July 29, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/xencor-xncr-expected-to-post-earnings-on-wednesday-2026-07-29/
EcoR1 Capital LLC Cuts Stock Holdings in Xencor, Inc. $XNCR
July 28, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-ecor1-capital-llc-cuts-stock-holdings-in-xencor-inc-xncr-2026-07-28/
Xencor (NASDAQ:XNCR) Stock Price Down 6.7% - Should You Sell?
July 22, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/xencor-nasdaqxncr-stock-price-down-67-should-you-sell-2026-07-22/
Xencor (NASDAQ:XNCR) Sets New 52-Week High - Should You Buy?
July 21, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/xencor-nasdaqxncr-sets-new-52-week-high-should-you-buy-2026-07-21/
Xencor (NASDAQ:XNCR) Sees Unusually-High Trading Volume - Here's Why
July 20, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/xencor-nasdaqxncr-sees-unusually-high-trading-volume-heres-why-2026-07-20/
Xencor (XNCR) Soars 16.9%: Is Further Upside Left in the Stock?
July 20, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2956079/xencor-xncr-soars-16-9-is-further-upside-left-in-the-stock?cid=cs-stocknewsapi-ft-tale_of_the_tape|daily_price_change_5%-2956079
Xencor: Strong Buy, XmAb819 Presentation, And End Of 2026 XmAb942 Interim Data
July 19, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4923333-xencor-strong-buy-xmab819-presentation-and-end-of-2026-xmab942-interim-data
Xencor Inc.
July 17, 2026  |  marketwatch.comhttps://www.marketwatch.com/investing/stock/XNCR/financials/cash-flow
Xencor advances 17% after revealing ESMO 2026 oral presentation slot
July 17, 2026  |  seekingalpha.comhttps://seekingalpha.com/news/4615067-xencor-advances-17-after-revealing-esmo-2026-oral-presentation-slot
Xencor (NASDAQ:XNCR) Stock Price Up 7.9% - What's Next?
July 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/xencor-nasdaqxncr-stock-price-up-79-whats-next-2026-07-17/
Xencor Announces Proffered Paper Oral Presentation at ESMO 2026 for Phase 1 Clinical Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma
July 17, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260716029119/en/xencor-announces-proffered-paper-oral-presentation-at-esmo-2026-for-phase-1-clinical-study-of-xmab819-in-advanced-clear-cell-renal-cell-carcinoma/
Xencor: Bullish On Their Increasingly In-House Pipeline
July 14, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4922052-xencor-bullish-on-their-increasingly-in-house-pipeline
Xencor (NASDAQ:XNCR) Shares Down 6.6% - Should You Sell?
July 13, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/xencor-nasdaqxncr-shares-down-66-should-you-sell-2026-07-13/
Xencor, Inc. (NASDAQ:XNCR) Receives Consensus Recommendation of "Moderate Buy" from Analysts
July 13, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/xencor-inc-nasdaqxncr-receives-consensus-recommendation-of-moderate-buy-from-analysts-2026-07-13/
Xencor Updates Outlook Amid Ultomiris Royalty Dispute
June 19, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/XNCR-Q/pressreleases/594951/xencor-updates-outlook-amid-ultomiris-royalty-dispute/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Dianthus Therapeutics stock logo

Dianthus Therapeutics NASDAQ:DNTH

$106.02 -0.90 (-0.84%)
Closing price 04:00 PM Eastern
Extended Trading
$106.02 0.00 (0.00%)
As of 05:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

Erasca stock logo

Erasca NASDAQ:ERAS

$17.84 -0.31 (-1.71%)
Closing price 04:00 PM Eastern
Extended Trading
$17.82 -0.02 (-0.09%)
As of 04:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

Grifols stock logo

Grifols NASDAQ:GRFS

$7.86 -0.01 (-0.13%)
Closing price 04:00 PM Eastern
Extended Trading
$7.86 0.00 (0.00%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development. Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG. It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1909 and is headquartered in Barcelona, Spain.

Xencor stock logo

Xencor NASDAQ:XNCR

$19.40 -0.81 (-4.01%)
Closing price 04:00 PM Eastern
Extended Trading
$19.39 -0.01 (-0.05%)
As of 04:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas